Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study.
Yilin ChenPeter MartinLurdes Y T InoueAnirban BasuJosh J CarlsonPublished in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2024)
The cost-effectiveness of TADs can vary by cancers. Using analytic tools such as external controls and Bayesian hierarchical models can tackle several challenges in assessing the value of TADs and uncertainties from basket trials.